Vera Therapeutics, Inc. (VERA) NASDAQ
31.26
-2.68(-7.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vera Therapeutics, Inc.
Address
8000 Marina Boulevard
Brisbane, CA 94005
United States of America (the)
Phone
650 770 0077
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
May 14, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1.21M | 1975 |
| William D. Turner | Chief Regulatory Officer | 737,880 | 1967 |
| Sean Grant | Chief Financial Officer | 793,920 | 1985 |
| Robert Brenner | Chief Medical Officer | 797,040 | 1968 |
| David L. Johnson | Chief Opearating Officer | 798,600 | 1970 |
| Amit Sharma FACP FASN FNKF | Executive Vice President of Medical Affairs | 0 | 1969 |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary | 0 | 1969 |
| Lijie Zhong | Senior Vice President of Biometrics | 0 | N/A |
| Raffaella Faggioni | SVP of Clinical Pharmacology & Translational Medicine | 0 | N/A |
| Thomas-Christian Mix | Executive Vice President of Clinical Development | 0 | 1967 |
| Gary Barrera | Senior Vice President of Regulatory Affairs & Quality Assurance | 0 | N/A |
| Jim Harrington | SVP of Intellectual Property | 0 | N/A |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1972 |
| Matthew Skelton | Chief Commercial Officer | 0 | 1965 |
| Carrie Helland | Senior Vice President of Product & Portfolio Strategy and Management | 0 | N/A |
| Debra Charlesworth | Vice President of Corporate Communications | 0 | N/A |
| Emma Haywood | Vice President of Marketing | 0 | N/A |
| Julie Person | Chief People Officer | 0 | 1973 |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | 0 | N/A |
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
